Related Experiment Video
Updated: Aug 6, 2026
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
A double-blind placebo-controlled study on prophylactic use of cisapride on feed intolerance and gastric emptying in
P S Reddy1, A K Deorari, C S Bal
1Departments of Pediatrics and Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110 029, India.
Insights
Prophylactic cisapride did not reduce feed intolerance or gastro-esophageal reflux in preterm infants. This study found no improvement in gastric emptying with cisapride use in neonates.
Area of Science:
- Neonatal Medicine
- Pediatric Gastroenterology
- Clinical Pharmacology
Background:
- Feed intolerance, gastro-esophageal reflux, and delayed gastric emptying are common concerns in preterm infants.
- Prophylactic medications are sometimes used to manage these issues in vulnerable neonates.
Purpose of the Study:
- To investigate the efficacy of prophylactic cisapride in reducing feed intolerance and gastro-esophageal reflux.
- To assess the impact of cisapride on improving gastric emptying in preterm neonates.
Main Methods:
- A double-blind, randomized controlled trial was conducted with 49 preterm infants (29-34 weeks gestation).
- Infants received either cisapride or placebo for 14 days, with assessments for feed intolerance, gastro-esophageal reflux, and gastric emptying via Technetium phytate scan.
Main Results:
- No significant difference was observed in the incidence or number of episodes of feed intolerance between the cisapride and placebo groups.
- Approximately 50% of infants in both groups experienced gastro-esophageal reflux.
- Gastric emptying time was comparable between the cisapride and placebo groups.
Conclusions:
- Prophylactic cisapride administration does not effectively reduce the incidence of feed intolerance or gastro-esophageal reflux in preterm neonates.
- Cisapride does not demonstrate a significant benefit in improving gastric emptying in this population.
Objective:
To evaluate whether prophylactic use of cisapride will reduce the incidence of feed intolerance and gastro-esophageal reflux, and improve gastric emptying in early neonatal period in preterm babies.
Design:
Double blind randomized controlled trial.
Setting:
Hospital based.
Subjects:
Forty nine preterm babies between 29-34 weeks of gestation were administered either cisapride or placebo.
Methods:
Babies were enrolled in the study once they reached 30 ml/kg/day of enteral feeding or when 25% of total fluid intake was received through the enteral route. Those with sepsis, congenital malformations and on aminophylline were excluded. The subjects were randomized to receive either cisapride or placebo in a dose of 0.2 mg/kg/dose every 8 hourly for 14 days or till discharge. During the study period babies were observed for clinical signs of feed intolerance as judged by increase in abdominal girth, increased prefeed gastric residuals or vomiting. Gastro-esophageal reflux and gastric emptying time was assessed by Technetium phytate scan on day 7 +/- 1.
Results:
Feed intolerance was noticed in 59% of study and 41% of control population. No significant difference was noticed in the two groups in the total number of episodes of feed intolerance (1.54 +/- 2.4 vs 1.18 +/- 1.6). Nearly 50% of babies in each group had gastro-esophageal reflux. Gastric emptying time (mean (SD) and median) was found to be comparable (p = 0.70) in those on drug and placebo (58.1 (32.2 min) 48.8 min) vs (53.8 (34.6 min) 43.4 min).
Conclusion:
Cisapride does not reduce the incidence of feed intolerance, gastro-esophageal reflux and does not improve gastric emptying in normal preterm neonates.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
01:11Pyloric Obstruction